Combining targeted therapies to treat difficult lung cancer cases
Synergistic combination of Proteolysis Targeting Chimera with a translational formulation for the treatment of intractable lung carcinoma
This study is testing a new way to treat advanced non-small cell lung cancer by using a special self-injectable medicine that targets specific proteins causing the cancer, with the hope of making treatments work better for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. John's University NIH-funded |
| Lab location | 1 site (Queens, United States) |
| Project ID | NIH-10580447 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for non-small cell lung cancer (NSCLC) by combining a novel drug delivery system with targeted therapies that degrade specific cancer-causing proteins. The study aims to develop a self-injectable, extended-release formulation that can effectively deliver these therapies to patients, potentially overcoming resistance to current treatments. By focusing on key oncogenic drivers like EGFR, KRAS, and MYC, the research seeks to improve treatment outcomes for patients with advanced lung cancer. Patients may be involved in trials to evaluate the safety and effectiveness of this new treatment method.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have developed resistance to existing therapies.
Not a fit: Patients with early-stage lung cancer or those without EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with resistant forms of lung cancer.
How similar studies have performed: While targeting multiple oncogenic drivers is a novel approach, similar strategies have shown promise in other cancer types, indicating potential for success in this area.
Where this research is happening
Queens, United States
- St. John's University — Queens, United States (Active)
Researchers
- Principal investigator: Patel, Ketankumar D. — St. John's University
- Study coordinator: Patel, Ketankumar D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.